Ulipristal Acetate (CDB 2914)

Catalog No.S3081 Synonyms: HRP 2000, RU 44675

For research use only.

Ulipristal acetate (CDB-2914, HRP 2000, RU 44675) is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.

Ulipristal Acetate (CDB 2914) Chemical Structure

CAS No. 126784-99-4

Selleck's Ulipristal Acetate (CDB 2914) has been cited by 2 Publications

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Other Estrogen/progestogen Receptor Products

Biological Activity

Description Ulipristal acetate (CDB-2914, HRP 2000, RU 44675) is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.
Targets
Progesterone receptor [1]
In vitro

Ulipristal acetate has partial agonistic as well as antagonistic effects on the progesterone receptor. It also binds to theglucocorticoid receptor, but has no relevant affinity to the estrogen, androgen and mineralocorticoid receptors.[1]

In vivo Based on clinical trials, ulipristal acetate seems to be a reasonably tolerable and effective method of emergency contraception when used within 120 hours of intercourse. Ulipristal acetate is at least as effective as LNG when used within the first 72 hours after unprotected intercourse. However, ulipristal acetate may be more effective than LNG when used between 72 to 120 hours after unprotected intercourse, extending the window of opportunity for emergency contraception. [2][3]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 83 mg/mL
(174.5 mM)
Water Insoluble
Ethanol ''''14 mg/mL

Chemical Information

Molecular Weight 475.62
Formula

C30H37NO4

CAS No. 126784-99-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)OC(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03349190 Completed Drug: ULIPRISTAL ACETATE Infertility Female|Fibroid Uterus ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO|Gedeon Richter Plc. December 29 2017 --
NCT03118297 Completed Drug: Ulipristal Acetate|Drug: Placebo oral capsule Contraception|Bleeding Washington University School of Medicine May 1 2017 Phase 3
NCT03156127 Withdrawn Drug: BR-UPS 5 mg tablet Inisia 5 mg tablet Uterine Myoma Boryung Pharmaceutical Co. Ltd May 19 2017 Phase 1
NCT02408770 Active not recruiting Drug: ulipristal acetate Breast Cancer Manchester University NHS Foundation Trust|University of Manchester March 29 2016 Phase 2
NCT02634437 Completed Drug: Ulipristal acetate Renal Function Allergan December 1 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ulipristal Acetate (CDB 2914) | Ulipristal Acetate (CDB 2914) ic50 | Ulipristal Acetate (CDB 2914) price | Ulipristal Acetate (CDB 2914) cost | Ulipristal Acetate (CDB 2914) solubility dmso | Ulipristal Acetate (CDB 2914) purchase | Ulipristal Acetate (CDB 2914) manufacturer | Ulipristal Acetate (CDB 2914) research buy | Ulipristal Acetate (CDB 2914) order | Ulipristal Acetate (CDB 2914) mouse | Ulipristal Acetate (CDB 2914) chemical structure | Ulipristal Acetate (CDB 2914) mw | Ulipristal Acetate (CDB 2914) molecular weight | Ulipristal Acetate (CDB 2914) datasheet | Ulipristal Acetate (CDB 2914) supplier | Ulipristal Acetate (CDB 2914) in vitro | Ulipristal Acetate (CDB 2914) cell line | Ulipristal Acetate (CDB 2914) concentration | Ulipristal Acetate (CDB 2914) nmr